National Institutes of Health Clinical Center (CC)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Institutes of Health Clinical Center (CC) sits in the top decile of US sponsors by registered trial count (#107 of 15,742 sponsors by registered trial count).

338 total trials 22 currently recruiting 272 completed early-phase tilt top decile by trial count

National Institutes of Health Clinical Center (CC): 338 sponsored US clinical trials, 22 recruiting.

National Institutes of Health Clinical Center (CC) sponsors 338 registered US clinical trials on ClinicalTrials.gov, 22 of them currently recruiting, and 272 completed. 17 of these trials are in Phase 3-4 (later-stage) and 121 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 8 trials.

Top-decile sponsor footprint

National Institutes of Health Clinical Center (CC) ranks in the top decile of sponsors by registered trial count (#107 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 60/100

272 of 308 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

338 total, page 5 of 7

COMPLETED

Influence of Genes on Sirolimus Metabolism in Patients With Kidney Transplantation

NCT00352547

COMPLETED Phase 1

Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

NCT00083057

COMPLETED

Isoproterenol Challenge to Detect Arrhythmogenic Right Ventricular Cardiomyopathy

NCT00083395

COMPLETED Phase 1

Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00085462

COMPLETED Phase 3

Oral Care to Reduce Mouth and Throat Infections in Critically Ill Patients

NCT00078663

COMPLETED Phase 2

Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma

NCT00077532

COMPLETED Phase 2

Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate

NCT00083005

COMPLETED

Patient-Provider Trust Among Individuals With End-Stage Kidney Disease

NCT00075036

COMPLETED

Magnetic Resonance Imaging to Evaluate Prostate Cancer

NCT00182624

COMPLETED NA

Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast Cancer

NCT00080860

COMPLETED Phase 1

Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer

NCT00078494

COMPLETED NA

Bupropion and Counseling With or Without Contingency Management to Enhance Smoking Cessation in Treating Cancer Survivors Who Continue to Smoke

NCT00079469

COMPLETED Phase 1

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

NCT00080925

COMPLETED

Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell Lymphoma

NCT00430053

COMPLETED Phase 1

The Effect of Lopinavir/Ritonavir on Endothelial Function

NCT00076414

COMPLETED

Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome

NCT00075348

COMPLETED

Citrate Effects and Bone Density in Long-Term Apheresis Donors

NCT00073060

COMPLETED Phase 1

Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease

NCT00072826

COMPLETED

Pharmacokinetic Interactions With Prednisolone in Healthy Volunteers and HIV-infected Patients Receiving Single-Dose Prednisone

NCT00072644

COMPLETED

Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations

NCT00070785

COMPLETED Phase 2

Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease

NCT00069316

COMPLETED

Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases

NCT00069342

COMPLETED

Natural History of West Nile Virus Infection

NCT00069303

COMPLETED

MR Perfusion Imaging and Hypercapnia (Increased Carbon Dioxide) to Study New Blood Vessel Formation in Multiple Sclerosis

NCT00064909

COMPLETED Phase 1

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

NCT00064311

COMPLETED NA

Serum Protein Patterns in Participants With Mycosis Fungoides/Cutaneous T-Cell Lymphoma, Psoriasis, or Normal Skin

NCT00066664

COMPLETED Phase 1

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

NCT00062036

COMPLETED Phase 2

Talampanel in Treating Patients With Recurrent High-Grade Glioma

NCT00064363

COMPLETED

Study of Heart Transplant Rejection

NCT00042614

COMPLETED Phase 1

Interleukin-7 in Treating Patients With Refractory Solid Tumors

NCT00062049

COMPLETED

Breathing Cycle Biofeedback During Computed Tomography Procedures

NCT00059137

COMPLETED

Development of Computer-aided Detection and Diagnosis From Imaging Techniques

NCT00057252

COMPLETED Phase 1

Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia

NCT00056433

COMPLETED Phase 1

Low-Dose rtPA to Treat Blood Clots in Major Arm or Neck Veins

NCT00055159

COMPLETED Phase 4

Differences in Blood Levels of Nevirapine in HIV-infected Patients in Uganda and the United States

NCT00054743

COMPLETED Phase 2

Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer

NCT00057889

COMPLETED NA

Study of Decision Making in Patients Participating in Phase I Clinical Trials

NCT00054223

COMPLETED Phase 4

Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers

NCT00050180

COMPLETED Phase 2

Daclizumab to Treat Chronic Immune Thrombocytopenia

NCT00049725

COMPLETED

Relationship Between Personality and Coping Styles in Bone Marrow Transplant Candidates

NCT00048256

COMPLETED

Ethical Dilemmas in Clinical Practice: A Survey of European Physicians

NCT00352573

COMPLETED Phase 1

Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy

NCT00047164

COMPLETED

The Natural History of Upper Trapezius Myofascial Trigger Points: Comparison of Local and Remote Tissue Milieu in Normal Muscle, Latent and Active Myofascial Trigger Points Over Time

NCT00042276

COMPLETED

Radiofrequency Ablation of Painful Soft Tissue Neoplasms

NCT00041886

COMPLETED NA

Evaluating Patient Participation in Phase I Clinical Trials

NCT00043030

COMPLETED Phase 3

Magnesium Effects in Apheresis

NCT00040235

COMPLETED Phase 1

Endothelial Dysfunction as a Risk Factor in HIV Study

NCT00039663

COMPLETED

Pilot Study: Effects of G-CSF on T Cell Function

NCT00039650

COMPLETED Phase 2

Heparin Versus Lepirudin Flushes in Preventing Blockage of Venous Access Devices

NCT00039767

COMPLETED Phase 4

Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients

NCT00034385

← Previous Page 5 of 7 Next →

Phase Distribution

PhaseTrial count
Phase 1 74
Phase 2 47
Phase 3 6
Phase 4 11

What is open in the National Institutes of Health Clinical Center (CC) pipeline

22 recruiting of 338 indexed (7% open); 272 completed (80%).

Phase mix: 17 late (III/IV) vs 121 early (I/II) (early-phase heavy).

Top condition: Healthy (8 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

National Institutes of Health Clinical Center (CC): open-pipeline peers nationwide

Peers matched on 338 registered trials and 7% open enrollment, not the therapeutic-area sidebar.

National Institutes of Health Clinical Center (CC) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 0%5%10%15%20%25% Total trials Recruiting share National Institutes of Health Clinical Center (CC)Cedars-Sinai Medical CenterOhio State University Comprehensive Cancer CenterNational Institute on Drug Abuse (NIDA)Children's Oncology GroupAlliance for Clinical Trials in OncologyNICHD Neonatal Research NetworkInsmed IncorporatedBaylor Breast Care Center
National Institutes of Health Clinical Center (CC) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

National Institutes of Health Clinical Center (CC) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 338 trials (± recruiting share)

Sponsors near 7% open enrollment (± trial volume)

What to do with this National Institutes of Health Clinical Center (CC) page

338 registered trials is a research-attention snapshot, not an endorsement of National Institutes of Health Clinical Center (CC) or any single study.

  • 22 of National Institutes of Health Clinical Center (CC)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy is the condition National Institutes of Health Clinical Center (CC) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institutes of Health Clinical Center (CC) pipeline card: 338 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.